Replimune Group (REPL) has disclosed a new risk, in the Accounting & Financial Operations category.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Replimune Group faces significant business risk due to identified material weaknesses in its internal control over financial reporting. These deficiencies, particularly in IT general controls, could lead to material misstatements in financial statements, potentially impairing compliance with laws and regulations. The ongoing remediation efforts are uncertain in timing and effectiveness, posing a threat to investor confidence and the company’s stock value. Failure to address these issues could also expose Replimune to risks of financial fraud, regulatory sanctions, and reputational damage.
Overall, Wall Street has a Moderate Buy consensus rating on REPL stock based on 2 Buys.
To learn more about Replimune Group’s risk factors, click here.